Remove 2011 Remove Drug Development Remove Immunization
article thumbnail

Understanding the microbiome as an ‘overlooked critical organ’

pharmaphorum

PubMed cites 1,822 pieces of research relating to the microbiome in 2011, which grew to 25,153 published in 2021. As more research has been conducted, closer and unexpected links have been found between the microbiome of the gut, as one example, and other areas of the body, such as brain health and the immune system.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates.

Immunity 135
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. In 2019, Del Bourgo and co-founder Julien Cottineau launched Whitelab Genomics and its AI platform dedicated to supporting the discovery and design of genomic therapies. “We